Giancarlo Comi.

In an additional prespecified exploratory analysis, the annualized price of relapse needing hospitalization or intravenous treatment with glucocorticoids, based on the treating neurologist’s decision, was significantly lower among sufferers receiving laquinimod as compared with those getting placebo . Disability End Points The risk of disability progression as assessed by an increase in EDSS scores that was sustained for three months was significantly reduced for patients receiving laquinimod, in comparison with those receiving placebo . This observation was reinforced by two findings from extra analyses: the risk of confirmed progression was considerably reduced with the use of the more stringent approach, which needed the persistence of the modification in the EDSS rating at the last obtainable assessment , and the actual proportion of patients with confirmed disability progression in the last evaluation was reduced the laquinimod group than in the placebo group .Afraxis to participate in NIH’s Therapeutics for Rare and Neglected Disease Program Afraxis, a San Diego-based biotechnology company developing drugs to take care of rare genetic illnesses through the modulation of p21-activated kinase , announced today that it’s been selected to take part in the National Institutes of Health’s Therapeutics for Rare and Neglected Disease Program. Within the program, Afraxis will partner with the NIH to go after the ongoing advancement of the business’s disease-modifying treatments for Fragile X syndrome.